LatestFDA Expert Panel Reviews Replimune's Experimental Melanoma Drug RP1
Health

FDA Expert Panel Reviews Replimune's Experimental Melanoma Drug RP1

Matthew Herper and Elaine Chen
FDA Expert Panel Reviews Replimune's Experimental Melanoma Drug RP1
Cancer
Summary

The FDA is conducting an expert review of Replimune's RP1, an experimental immunotherapy treatment for melanoma. RP1 is designed to harness the body's immune system to fight melanoma cells more effectively. This regulatory milestone represents a critical step toward potential approval of a new treatment option for patients with this serious skin cancer. The outcome of this expert panel review could determine whether RP1 becomes available to melanoma patients who need additional therapeutic options.

Stat News

Originally published on

STAT News

By Matthew Herper and Elaine Chen

Read full article(opens in new tab)

Fetched: July 30, 2026 at 10:01 AM

Related News

More news you might be interested in

View all
U.S. Navy Transfers Three Parcels to Advance Roosevelt Roads Redevelopment
Health

U.S. Navy Transfers Three Parcels to Advance Roosevelt Roads Redevelopment

The U.S. Navy has formalized the transfer of three additional parcels to the Local Redevelopment Authority (LRA) of Roosevelt Roads, advancing the economic revitalization project in Puerto Rico. Licensed Carlos J. Ríos Pierluski, executive director of the LRA and secretary of the Department of Economic Development and Commerce (DDEC), announced this significant milestone. The transfer represents continued progress in transforming the former naval base into a hub for economic development and job creation. This initiative is part of Puerto Rico's broader strategy to diversify its economy and strengthen local communities through strategic infrastructure development.

1 hour ago
NotiCel
Corruption Scandal Shakes Colombian Government Days Before Presidential Transition
Health

Corruption Scandal Shakes Colombian Government Days Before Presidential Transition

Colombian President Gustavo Petro faces a corruption scandal in the final days of his administration before Abelardo de la Espriella assumes office on August 7 for the 2026-2030 term. Cross-accusations among top government officials have placed the president under scrutiny during this critical political transition period. While primarily a political matter, such governmental instability can impact public health infrastructure and healthcare service continuity in the region. Healthcare systems depend on stable governance and proper resource allocation for effective patient care delivery.

1 hour ago
NotiCel
The Witness Who Records But Doesn't Testify
Health

The Witness Who Records But Doesn't Testify

A growing phenomenon is occurring in Puerto Rico where witnesses record crimes on their phones, share videos on social media, and then disappear. While the videos go viral and generate public outrage, reaching mainstream media outlets, authorities struggle to locate the original witnesses for formal testimony and evidence authentication. This pattern raises important questions about civic responsibility, legal obligations, and the role of social media in criminal justice. When witnesses fail to come forward officially, it can compromise investigations and weaken cases against perpetrators.

1 hour ago
NotiCel
Planning Board Intervenes in Camuy's Dispute with DRNA Over Unauthorized Construction
Health

Planning Board Intervenes in Camuy's Dispute with DRNA Over Unauthorized Construction

Superior Court Judge Gerardo Rafael Sarriera Lázaro indicated he could rule as early as next week on the Municipality of Camuy's lawsuit challenging a work stoppage and cease-and-desist order issued by the Department of Natural and Environmental Resources (DRNA) regarding alleged unauthorized construction projects. The Planning Board has intervened in support of Camuy's position in this ongoing environmental and regulatory dispute. This legal development addresses concerns about construction permitting procedures and environmental compliance in Puerto Rico.

1 hour ago
NotiCel